TW201741B - - Google Patents

Download PDF

Info

Publication number
TW201741B
TW201741B TW081100798A TW81100798A TW201741B TW 201741 B TW201741 B TW 201741B TW 081100798 A TW081100798 A TW 081100798A TW 81100798 A TW81100798 A TW 81100798A TW 201741 B TW201741 B TW 201741B
Authority
TW
Taiwan
Prior art keywords
compound
item
dimethyl
guanidine
patent application
Prior art date
Application number
TW081100798A
Other languages
English (en)
Chinese (zh)
Original Assignee
Squibb & Sons Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Squibb & Sons Inc filed Critical Squibb & Sons Inc
Application granted granted Critical
Publication of TW201741B publication Critical patent/TW201741B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/68—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with nitrogen atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/70—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with two hydrocarbon radicals attached in position 2 and elements other than carbon and hydrogen in position 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/6552—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring
    • C07F9/65522—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/657163—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom
    • C07F9/657181—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom the ring phosphorus atom and, at least, one ring oxygen atom being part of a (thio)phosphonic acid derivative

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pyrane Compounds (AREA)
TW081100798A 1991-02-27 1992-02-01 TW201741B (el)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/661,763 US5140031A (en) 1989-05-31 1991-02-27 Pyranyl cyanoguanidine derivatives

Publications (1)

Publication Number Publication Date
TW201741B true TW201741B (el) 1993-03-11

Family

ID=24655020

Family Applications (1)

Application Number Title Priority Date Filing Date
TW081100798A TW201741B (el) 1991-02-27 1992-02-01

Country Status (19)

Country Link
US (1) US5140031A (el)
EP (1) EP0501797B1 (el)
KR (1) KR920016437A (el)
CN (1) CN1035253C (el)
AT (1) ATE138919T1 (el)
AU (1) AU650512B2 (el)
CA (1) CA2061699C (el)
CY (1) CY1952A (el)
DE (1) DE69211182T2 (el)
DK (1) DK0501797T3 (el)
ES (1) ES2088537T3 (el)
GR (1) GR3020647T3 (el)
HK (1) HK161396A (el)
IE (1) IE920346A1 (el)
IL (1) IL101012A0 (el)
MX (1) MX9200817A (el)
NO (1) NO180679C (el)
TW (1) TW201741B (el)
ZA (1) ZA921333B (el)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643921A (en) * 1990-09-26 1997-07-01 E.R. Squibb & Sons, Inc. Cardiopulmonary bypass and organ transplant using a potassium channel activator
US5401848A (en) * 1990-11-26 1995-03-28 E. R. Squibb & Sons, Inc. Indane and quinoline derivatives
US5262419A (en) * 1992-06-11 1993-11-16 E. R. Squibb & Sons, Inc. Method for the prophylaxis and/or treatment of ulcerative gastrointestinal conditions using a potassium channel activator
US5374643A (en) * 1992-09-11 1994-12-20 E. R. Squibb & Sons, Inc. Aryl urea (thiourea) and cyanoguanidine derivatives
US5453421A (en) * 1992-09-11 1995-09-26 E. R. Squibb & Sons, Inc. Aryl and heterocyclic substituted propenamide derivatives
US5463059A (en) * 1992-11-10 1995-10-31 E. R. Squibb & Sons, Inc. Process for the preparation of intermediates useful in the preparation of pyranyl cyanoguanidine derivatives
US5514690A (en) * 1992-11-17 1996-05-07 E. R. Squibb & Sons, Inc. Aminocarbonyl (thiocarbonyl) and cyanoguanidine derivatives of quinoline and indoline
IL109229A0 (en) * 1993-05-11 1994-07-31 Bristol Myers Squibb Co Heterocyclic compounds and processes for the preparation of pyranyl cyanoguanidine derivatives using the same
US5393771A (en) * 1993-05-12 1995-02-28 Brisol-Myers Squibb Company 4-substituted benzopyran and related compounds
US5478734A (en) * 1993-06-18 1995-12-26 Bristol-Myers Squibb Company Method of chiral epoxidation of benzopyran or pyranopyridine derivatives using microorganisms
TW310327B (el) * 1993-06-18 1997-07-11 Bristol Myers Squibb Co
US5691344A (en) * 1993-08-19 1997-11-25 Janssen Pharmaceutica, N.V. Vasoconstrictive substituted dihydropyranopyridines
US5401758A (en) * 1993-10-07 1995-03-28 Bristol-Myers Squibb Company Pyridinyl cyanoguanidine compounds
US5837702A (en) * 1993-10-07 1998-11-17 Bristol-Myers Squibb Co. 4-arylamino-benzopyran and related compounds
US5547966A (en) * 1993-10-07 1996-08-20 Bristol-Myers Squibb Company Aryl urea and related compounds
US5679706A (en) * 1994-09-30 1997-10-21 Bristol-Myers Squibb Company Combination of a potassium channel activator and an antiarrhythmic agent
US5629429A (en) * 1995-06-07 1997-05-13 Bristol-Myers Squibb Company Process for preparing 4-arylamino-benzopyran and related compounds
US5869478A (en) * 1995-06-07 1999-02-09 Bristol-Myers Squibb Company Sulfonamido substituted benzopyran derivatives
US5612323A (en) * 1995-06-07 1997-03-18 Bristol-Myers Squibb Company Phosphinic ester substituted benzopyran derivatives
US5612370A (en) * 1995-06-07 1997-03-18 Bristol-Myers Squibb Company Phenylglycine and phenylalaninen amido benzopyran derivatives
CA2341678C (en) 1998-09-01 2009-10-13 Bristol-Myers Squibb Company Potassium channel inhibitors and method
US6417207B1 (en) 1999-05-12 2002-07-09 Nitromed, Inc. Nitrosated and nitrosylated potassium channel activators, compositions and methods of use
US6645968B2 (en) * 1999-08-03 2003-11-11 Abbott Laboratories Potassium channel openers
MXPA02001207A (es) * 1999-08-03 2002-07-30 Abbott Lab Abridores de canal de potasio.
DE60007168T2 (de) * 1999-10-21 2004-12-30 Dongbu Hannong Chemical Co., Ltd. Benzopyranyl-guanidin-derivate, verfahren zu deren herstellung sowie diese enthaltenden pharmazeutische zusammensetzungen
KR100429609B1 (ko) * 1999-10-21 2004-05-03 동부한농화학 주식회사 벤조피라닐 구아니딘 유도체, 그의 제조방법 및 그를포함하는 약학적 조성물
DE60234057D1 (de) 2001-07-25 2009-11-26 Raptor Pharmaceutical Inc Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke
CN1854135B (zh) * 2005-04-18 2013-06-12 李伟章 由氰基胍连接组成的杂环化合物及其医药应用
EP2392258B1 (en) 2005-04-28 2014-10-08 Proteus Digital Health, Inc. Pharma-informatics system
US7999107B2 (en) 2007-01-31 2011-08-16 Merck Sharp & Dohme Corp. Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators
US8795627B2 (en) 2007-03-21 2014-08-05 Raptor Pharmaceuticals Inc. Treatment of liver disorders by administration of RAP conjugates
US20110020453A1 (en) * 2009-02-06 2011-01-27 Steven Blum Topical Formulations Comprising Ion Channel Modulators
AU2010216512B2 (en) 2009-02-20 2016-06-30 2-Bbb Medicines B.V. Glutathione-based drug delivery system
WO2010129819A2 (en) 2009-05-06 2010-11-11 Laboratory Skin Care, Inc. Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3682331D1 (de) * 1985-06-08 1991-12-12 Beecham Group Plc Pyrano(3,2-c)pyridinderivate, verfahren und zwischenprodukte zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen.
US4639701A (en) * 1985-08-30 1987-01-27 Westinghouse Electric Corp. Circuit breaker with interface flux shunt trip
GB8521857D0 (en) * 1985-09-03 1985-10-09 Beecham Group Plc Active compounds
GB8613786D0 (en) * 1986-06-06 1986-07-09 Beecham Group Plc Active compounds
GB8625185D0 (en) * 1986-10-21 1986-11-26 Beecham Group Plc Active compounds
US4988723A (en) * 1988-06-02 1991-01-29 Fujisawa Pharmaceutical Co., Ltd. Benzopyran derivatives and their use as anti-hypertensives
DE3823533A1 (de) * 1988-07-12 1990-02-08 Beiersdorf Ag Substituierte 4-heterocyclyl-2h-benzo(b)pyrane, verfahren und 4-hydroxy-3-brom-, 3,4-oxiranyl-3,4-dehydro-2h-benzo(b)pyrane als zwischenprodukte zu ihrer herstellung, sowie sie enthaltende pharmazeutsche praeparate
CA1336963C (en) * 1988-07-18 1995-09-12 Gary James Grover Method for inhibiting myocardial cell necrosis and preserving heart function during myocardial ischemia and/or reperfusion
DE68926729T2 (de) * 1988-09-16 1997-02-13 Beecham Group Plc Benzopyranderivate mit einer blutdrucksenkenden Wirkung
US5104890A (en) * 1989-03-28 1992-04-14 Fujisawa Pharmaceutical Company, Ltd. Benzopyran derivatives and processes for preparation thereof
CA2015296C (en) * 1989-05-31 2001-08-07 Karnail Atwal Pyranyl cyanoguanidine derivatives
US5095016A (en) * 1989-08-11 1992-03-10 Kaken Pharmaceutical Co., Ltd. Benzopyran compounds, processes for their production and pharmaceutical compositions
CN1080721C (zh) * 1995-07-03 2002-03-13 旭化成株式会社 1－(5－异喹啉磺酰基)高哌嗪盐酸盐水合物

Also Published As

Publication number Publication date
MX9200817A (es) 1992-08-01
AU650512B2 (en) 1994-06-23
CA2061699C (en) 2002-05-21
CA2061699A1 (en) 1992-08-28
IL101012A0 (en) 1992-11-15
NO180679B (no) 1997-02-17
ES2088537T3 (es) 1996-08-16
IE920346A1 (en) 1992-09-09
EP0501797B1 (en) 1996-06-05
US5140031A (en) 1992-08-18
CN1064272A (zh) 1992-09-09
CY1952A (en) 1997-05-16
NO920767L (no) 1992-08-28
ATE138919T1 (de) 1996-06-15
NO180679C (no) 1997-05-28
NO920767D0 (no) 1992-02-26
AU1114792A (en) 1992-09-03
DK0501797T3 (da) 1996-06-24
DE69211182T2 (de) 1997-01-23
ZA921333B (en) 1992-11-25
CN1035253C (zh) 1997-06-25
KR920016437A (ko) 1992-09-24
GR3020647T3 (en) 1996-10-31
EP0501797A1 (en) 1992-09-02
DE69211182D1 (de) 1996-07-11
HK161396A (en) 1996-09-06

Similar Documents

Publication Publication Date Title
TW201741B (el)
RU2057129C1 (ru) Способ получения производных пиранил-цианогуанидина
MXPA06013374A (es) Aril-acil-tioureas sustituidas y compuestos relacionados, inhibidores de la replica viral.
CA2962329C (en) Heterocyclic compounds and use thereof
PT98019A (pt) Processo para a preparacao de composicoes farmaceuticas contendo derivados e benzopiran e analogos heterociclicos dos mesmos utilizados como agentes anti-isquemicos
CN102118969A (zh) 组胺h4受体的二氨基吡啶、二氨基嘧啶和二氨基哒嗪调节剂
JP2020533335A (ja) アポトーシスシグナル調節キナーゼ阻害剤およびその使用
CN106795141A (zh) 用于治疗病毒感染的异吲哚啉衍生物
CA2965781A1 (en) Heterocyclic derivative having ampk activating effect
AU604525B2 (en) Substituted 3,4-dihydro-2h-benzopyrans, processes for their preparation, their use and pharmaceutical products based on these compounds
JPH0570347A (ja) 臓器用保護剤
JP2023516824A (ja) ヒストン脱アセチル化酵素６阻害剤としての１，３，４－オキサジアゾール誘導体化合物、およびそれを含む医薬組成物
CN107250120A (zh) 作为Wnt信号通路抑制剂的1,3,4‑噻二唑‑2‑基‑苯甲酰胺衍生物
CA2387727C (en) Benzopyranyl guanidine derivatives, process for preparation thereof, and pharmaceutical compositions containing them
US6323238B1 (en) Benzopyranyl guanidine derivatives, process for preparation thereof, and pharmaceutical compositions containing them
AU2021328979A9 (en) Pyrazole boronic acid compound, pharmaceutical composition containing same, and uses thereof
CA3157279A1 (en) Trpv4 receptor ligands
JPH05117233A (ja) インドールおよびジヒドロキノリンカリウム管開放剤
CA3181071A1 (en) Indole derivatives and uses thereof for treating a cancer
RU2061694C1 (ru) Производные индола
WO2022226203A1 (en) Protease inhibitors and methods of use
WO2012112733A1 (en) Cathepsin c inhibitors
WO2020036949A1 (en) Ask1 inhibiting agents
KR19990044287A (ko) 피브리노겐 수용체 길항물질 및 전기 물질을 유효 성분으로 하는 의약제제
NZ245300A (en) Protecting organs from ischemic damage using 4-(cyanoguanidine)benzopyran derivatives